Trial Profile

Assessment of Safety and Efficacy of Zanubrutinib in Patients With Various B-cell Malignancies (Small Lymphocytic Lymphoma Chronic Lymphocytic Leukemia); A Global, Open-label, Multicenter, Phase I/II Trial

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Dec 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Dec 2019 New trial record
06 Nov 2019 Results (N=122), focusing high overall response rate and durable responses in patients with various B-cell malignancies; updated results from a phase 1/2 study, released at the 61st Annual Meeting and Exposition of the American Society of Hematology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com